Ovarian cancer is the fifth most deadly cancer in women and represents a major unmet medical need. Folate receptor α (FRα) is an antigen present on over 70% of ovarian cancers and is also expressed on a variety of other cancers notably non-small cell lung, endometrial cancer and triple negative breast cancer (TNBC). While FRα is overexpressed in these cancers, it has very low expression across non-malignant tissues making it an ideal cancer target.
MOv18 IgE is a therapeutic antibody targeting FRα and is the world’s first IgE antibody to enter the clinic. It has successfully completed a phase I trial in cancer patients with advanced solid tumours expressing FRα. The antibody was found to be safe and well tolerated with initial signs of clinical activity also seen. The results of the trial were published in Nature Communications.
Recent data on MOv18 IgE was also shared in a poster presentation at ESGO 2025, see it here.
Clinical Trial
We are actively recruiting for a Phase Ib trial in the UK focussed on Platinum Resistant Ovarian Cancer (PROC) (NCT06547840). The primary aim of this trial is to explore the safe and effective treatment of patients with PROC, using MOv18 IgE.
To volunteer to take part in Epsilogen’s Phase Ib trial of MOv18 IgE in Folate Receptor α-expressing Platinum Resistant Ovarian Cancer click on the link below:
Be Part of Research – Trial Details